Solid Biosciences heads into mid-June with a notable split: short sellers are quietly adding to already-elevated positions, while every analyst covering the stock maintains a bullish rating and targets that sit well above the current price.
Short interest is the most pressing data point here. Bears control 12.3% of the free float — a high reading for a small-cap biotech — and that position has grown roughly 8% over the past month to around 9.6 million shares. The direction of travel is steady rather than dramatic: shorts added incrementally almost every session this week, with the weekly increase running just under 5%. Despite the scale of the short position, the borrow market offers no squeeze signal. Availability is generous at roughly 587% — meaning lenders hold nearly six shares available for every share already borrowed — well above the 52-week floor of 302%. Cost to borrow has ticked up 55% over the week but remains trivially low at 0.56%, so the economics of maintaining a short position are essentially costless. The ORTEX short score of 65, while meaningfully elevated, has drifted down from a recent peak of 66.4 on June 10, suggesting the bearish conviction has plateaued rather than intensified. Options traders are relaxed: the put/call ratio sits at 0.54, barely above its 20-day average of 0.53 and far below any prior spike readings, so there is no sign of defensive hedging pressure in the derivatives market.
The Street's view stands in sharp contrast to the short book. Every analyst covering SLDB carries a Buy or Outperform rating. HC Wainwright raised its target to $25 in early June, and Guggenheim initiated coverage in March with a $26 target — both implying more than three times the current price of $7.07. Piper Sandler carries an $18 Overweight, Wedbush an $16 Outperform, and JP Morgan an $12 Overweight; the consensus target across the group is approximately $17.40, roughly 2.5 times where the stock trades now. The bull case centres on the gene therapy pipeline: SGT-003 is advancing through a pivotal Phase 3 study in Duchenne muscular dystrophy, and the company recently dosed two patients with SGT-212 in Friedreich's ataxia. Bears point to the absence of any approved product, a small addressable patient population, persistent cash burn (EV/EBITDA of -2.1 reflects the pre-revenue reality), and the ever-present risk of regulatory setback. The price-to-book multiple has expanded about 28% over the past month to nearly 6x as the stock rallied, which compresses the margin of safety even against optimistic pipeline scenarios.
Institutional ownership tells a story of specialist conviction. Perceptive Advisors holds 12.1% of shares, Bain Capital Life Sciences 10%, and RA Capital nearly 9.5% — the latter added more than 3.5 million shares in the quarter to March. Vestal Point Capital built a 5% position from scratch in the same period, and Janus Henderson and Deep Track Capital both initiated entirely new positions. Fidelity (FMR) added 1.6 million shares. The pattern is a cluster of healthcare-specialist funds deepening exposure, not passive index flows — which tends to mean the holders have a thesis tied to specific pipeline milestones rather than sector drift.
Recent earnings history adds a layer of asymmetry. The June 10 readout triggered a nearly 10% single-day gain. The May 12 print went the other way — down 4% the next day, and down 21% over the following five sessions. The next scheduled event is August 12, which gives the short book roughly eight weeks of runway before the next binary catalyst.
The stock is up 8% on the week and 2% over the past month, though it fell 4% on Tuesday. Closest correlated peers had a mixed week: MRNA surged 16% and DYN added 0.8%, while EDIT fell 11% and DNTH dropped 7%, leaving the gene-therapy sector without a clear directional read. With August 12 now firmly in view, the next focal point is whether pipeline updates — particularly on SGT-003 Phase 3 enrollment or any interim data signal — emerge before then, and whether the specialist holders who built positions this spring use any weakness to add further.
See the live data behind this article on ORTEX.
Open SLDB on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
